Prescription rates for drugs used in treatment of benign prostatic hyperplasia and erectile dysfunction before and after prostate cancer diagnosis.

Anne Katrine Duun-Henriksen Christian Dehlendorff Martin Andreas Røder Charlotte Skriver Jesper HallasSøren FriisMartin Andreas Røder Signe Benzon Larsen

Published in: Acta oncologica (Stockholm, Sweden) (2022)

Differences in prescription rates suggest increased prostate cancer surveillance among men receiving BPH drugs, whereas the post-diagnostic increase in ED drugs among men with localized disease is compatible with the increased risk of ED following prostate cancer treatment.

Keyphrases

benign prostatic hyperplasia
prostate cancer
lower urinary tract symptoms
radical prostatectomy
emergency department
drug induced
replacement therapy